Advertisement

Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?

Published:January 11, 2022DOI:https://doi.org/10.1016/j.clgc.2022.01.006

      Highlights

      • The penile bulb (PB) is an important organ-at-risk(OAR) to consider for sexual morbidity when delivering prostate cancer RT
      • Inter-fraction changes to PB during MRI-guided RT in the post-radical prostatectomy (RP) setting were evaluated
      • There were no significant differences in PB volume, positional change, or mean dose during RT
      • Findings indicate that PB organ motion may not need to be accounted for in radiation treatment planning
      • Validation study with larger sample size is warranted

      Abstract

      Background

      We evaluated inter-fraction penile bulb (PB) changes in prostate cancer (PCa) patients undergoing MR-guided RT in the post-radical prostatectomy (RP) setting.

      Materials and Methods

      10 patients with PCa status-post RP received MR-guided RT from 2017-2019. Patients received daily setup volumetric MRI scans prior to RT delivery for alignment and target localization. Setup MRI datasets from Fx 1, Fx 19, and Fx 37 were fused for each patient based on soft tissue anatomy. The PB was contoured on each MRI. Data on volume (cc), superior/inferior positional change (cm), and mean dose (Gy) was collected. Differences were assessed by Student’s t-test (sig. p<0.05).

      Results

      The mean PB volume change from Fx 1→ 19 was +0.34 ± 0.34 cc (p=0.11) and from Fx 1→ 37 was +0.22 ± 0.28 cc (p=0.31). The mean positional change from Fx 1→ 19 was +0.08±0.26 cm (p=0.37) and from Fx 1→ 37 was +0.05 ±0.25 cm (p=0.57). The mean change in mean PB dose from Fx 1→ 19 was +0.19±4.86 Gy (p=0.98) and from Fx 1→ 37 was -1.51≖7.46 Gy (p=0.88).

      Conclusion

      We present the first study evaluating inter-fraction changes to the PB during MR-guided RT. We found no clinically meaningful difference in the volume, positional change, or mean dose during RT in the post-prostatectomy setting, suggesting that PB organ motion may not need to be accounted for in radiation treatment planning.

      Keywords

      Abbreviations:

      RP (radical prostatectomy), PB (penile bulb), PCa (prostate cancer), Fx (fraction of radiation)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Donovan JL
        • Hamdy FC
        • Lane JA
        • et al.
        Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer.
        N Engl J Med. 2016; 375: 1425-1437https://doi.org/10.1056/NEJMoa1606221
        • Sanda MG
        • Dunn RL
        • Michalski J
        • et al.
        Quality of life and satisfaction with outcome among prostate-cancer survivors.
        N Engl J Med. 2008; 358: 1250-1261https://doi.org/10.1056/NEJMoa074311
        • Wallis CJD
        • Zhao Z
        • Huang LC
        • et al.
        Association of treatment modality, functional outcomes, and baseline characteristics with treatment-related regret among men with localized prostate cancer.
        JAMA Oncol. 2021; (Published online)https://doi.org/10.1001/jamaoncol.2021.5160
        • Zelefsky MJ
        • Eid JF
        Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer.
        Int J Radiat Oncol. 1998; 40: 129-133https://doi.org/10.1016/S0360-3016(97)00554-3
        • Walsh PC
        • Donker PJ.
        Impotence following radical prostatectomy: insight into etiology and prevention.
        J Urol. 1982; 128: 492-497https://doi.org/10.1016/s0022-5347(17)53012-8
        • Stanford JL
        • Feng Z
        • Hamilton AS
        • et al.
        Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study.
        JAMA. 2000; 283: 354-360https://doi.org/10.1001/jama.283.3.354
        • Roach M
        • Nam J
        • Gagliardi G
        • Naqa IE
        • Deasy JO
        • Marks LB.
        Radiation dose–volume effects and the penile bulb.
        Int J Radiat Oncol Biol Phys. 2010; 76 (Suppl): S130-S134https://doi.org/10.1016/j.ijrobp.2009.04.094
        • Zaorsky NG
        • Showalter TN
        • Ezzell GA
        • Nguyen PL
        • Assimos DG
        • D’Amico AV
        • et al.
        ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.
        Adv Radiat Oncol. 2017; 2: 62-84https://doi.org/10.1016/j.adro.2016.10.002
        • Zaorsky NG
        • Showalter TN
        • Ezzell GA
        • et al.
        ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.
        Adv Radiat Oncol. 2017; 2: 437-454https://doi.org/10.1016/j.adro.2017.03.003
        • Wallner KE
        • Merrick GS
        • Benson ML
        • Butler WM
        • Maki J
        • Tollenaar BG.
        Penile bulb imaging.
        Int J Radiat Oncol. 2002; 53: 928-933https://doi.org/10.1016/S0360-3016(02)02805-5
        • Steenbakkers RJHM
        • Deurloo KEI
        • Nowak PJCM
        • Lebesque JV
        • Herk M van, Rasch CRN.
        Reduction of dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate.
        Int J Radiat Oncol Biol Phys. 2003; 57: 1269-1279https://doi.org/10.1016/S0360-3016(03)01446-9
        • Agrawal V
        • Farjam RF
        • Nagar H
        • et al.
        Real-time MRI-guided prostate stereotactic body radiation therapy: impact on treatment delivery and implications.
        Int J Radiat Oncol Biol Phys. 2019; 105: E260https://doi.org/10.1016/j.ijrobp.2019.06.1964
        • Tetar SU
        • Bruynzeel AME
        • Lagerwaard FJ
        • Slotman BJ
        • Bohoudi O
        • Palacios MA.
        Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer.
        Phys Imaging Radiat Oncol. 2019; 9: 69-76https://doi.org/10.1016/j.phro.2019.02.002
        • Fischer-Valuck BW
        • Henke L
        • Green O
        • et al.
        Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system.
        Adv Radiat Oncol. 2017; 2: 485-493https://doi.org/10.1016/j.adro.2017.05.006
        • Henke LE
        • Contreras JA
        • Green OL
        • et al.
        Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A 4.5-year clinical experience.
        Clin Oncol. 2018; 30: 720-727https://doi.org/10.1016/j.clon.2018.08.010
        • Henke LE
        • Contreras JA
        • Mazur T
        • et al.
        Delineation of a cardiac planning organ-at-risk volume using real-time magnetic resonance imaging for cardiac protection in thoracic and breast radiation therapy.
        Pract Radiat Oncol. 2019; 9: e298-e306https://doi.org/10.1016/j.prro.2018.12.004
        • Henke L
        • Kashani R
        • Robinson C
        • et al.
        Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.
        Radiother Oncol. 2018; 126: 519-526https://doi.org/10.1016/j.radonc.2017.11.032
        • Saldi S
        • Bellavita R
        • Lancellotta V
        • et al.
        Acute toxicity profiles of hypofractionated adjuvant and salvage radiation therapy after radical prostatectomy: results of a prospective study.
        Int J Radiat Oncol Biol Phys. 2019; 103: 105-111https://doi.org/10.1016/j.ijrobp.2018.08.016
        • Sampath S
        • Frankel P
        • Vecchio BD
        • et al.
        Stereotactic body radiation therapy to the prostate bed: results of a phase 1 dose-escalation trial.
        Int J Radiat Oncol Biol Phys. 2020; 106: 537-545https://doi.org/10.1016/j.ijrobp.2019.11.005
        • Michalski JM
        • Lawton C
        • Naqa IE
        • et al.
        Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2010; 76: 361https://doi.org/10.1016/j.ijrobp.2009.02.006
        • de Muinck Keizer DM
        • Kerkmeijer LGW
        • Willigenburg T
        • et al.
        Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac.
        Radiother Oncol. 2020; 151: 88-94https://doi.org/10.1016/j.radonc.2020.06.044
        • Gay HA
        • Barthold HJ
        • O'Meara E
        • et al.
        Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas.
        Int J Radiat Oncol Biol Phys. 2012; 83: e353-e362https://doi.org/10.1016/j.ijrobp.2012.01.023
        • Smith DP
        • Supramaniam R
        • King MT
        • Ward J
        • Berry M
        • Armstrong BK.
        Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer.
        J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25: 2560-2566https://doi.org/10.1200/JCO.2006.09.8046
        • Selek U
        • Cheung R
        • Lii M
        • et al.
        Erectile dysfunction and radiation dose to penile base structures: a lack of correlation.
        Int J Radiat Oncol Biol Phys. 2004; 59: 1039-1046https://doi.org/10.1016/j.ijrobp.2003.12.028
        • van der Wielen GJ
        • Hoogeman MS
        • Dohle GR
        • van Putten WLJ
        • Incrocci L.
        Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial.
        Int J Radiat Oncol Biol Phys. 2008; 71: 795-800https://doi.org/10.1016/j.ijrobp.2007.10.052
        • Wernicke AG
        • Valicenti R
        • Dieva K
        • Houser C
        • Pequignot E.
        Radiation dose delivered to the proximal penis as a predictor of the risk of erectile dysfunction after three-dimensional conformal radiotherapy for localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1357-1363https://doi.org/10.1016/j.ijrobp.2004.05.030
        • Roach M
        • Winter K
        • Michalski JM
        • et al.
        Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1351-1356https://doi.org/10.1016/j.ijrobp.2004.05.026
        • Rasmusson E
        • Gunnlaugsson A
        • Wieslander E
        • et al.
        Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultrahypofractionated and conventionally fractionated radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2020; 107: 143-151https://doi.org/10.1016/j.ijrobp.2020.01.022
        • Jaccard M
        • Lamanna G
        • Dubouloz A
        • Rouzaud M
        • Miralbell R
        • Zilli T.
        Dose optimization and endorectal balloon for internal pudendal arteries sparing in prostate SBRT.
        Phys Medica PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB. 2019; 61: 28-32https://doi.org/10.1016/j.ejmp.2019.04.008
        • Murray J
        • Gulliford S
        • Griffin C
        • et al.
        Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
        Clin Transl Radiat Oncol. 2020; 21: 77-84https://doi.org/10.1016/j.ctro.2019.12.006
        • Hamstra DA
        • Mariados N
        • Sylvester J
        • et al.
        Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial.
        Pract Radiat Oncol. 2018; 8: e7-e15https://doi.org/10.1016/j.prro.2017.07.008
        • Burt LM
        • Shrieve DC
        • Tward JD.
        Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database.
        Adv Radiat Oncol. 2018; 3: 170-180https://doi.org/10.1016/j.adro.2017.12.008
        • Agrawal V
        • Ma X
        • Hu JC
        • Barbieri CE
        • Nagar H.
        Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US.
        JAMA Netw Open. 2020; 3e2014674https://doi.org/10.1001/jamanetworkopen.2020.14674
        • Soloway M
        • Roach M.
        Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era.
        Cancer. 2005; 104: 2310-2322https://doi.org/10.1002/cncr.21441
        • Morgan SC
        • Hoffman K
        • Loblaw DA
        • et al.
        Hypofractionated radiation therapy for localized prostate cancer: executive summary of an astro, asco, and aua evidence-based guideline.
        Pract Radiat Oncol. 2018; 8: 354-360https://doi.org/10.1016/j.prro.2018.08.002
        • Mitin T
        • Henry A
        • Choudhury A
        • Chen RC
        • Pinkawa M
        • Spratt DE.
        SBRT for localized prostate cancer: is it ready for take-off?.
        Int J Radiat Oncol Biol Phys. 2019; 105: 618-620https://doi.org/10.1016/j.ijrobp.2019.07.008
        • Martell K
        • Mendez LC
        • Chung HT
        • et al.
        Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.
        Radiother Oncol. 2019; 141: 149-155https://doi.org/10.1016/j.radonc.2019.08.017
        • Connolly JA
        • Shinohara K
        • Presti JC
        • Carroll PR.
        Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins.
        Urology. 1996; 47: 225-231https://doi.org/10.1016/S0090-4295(99)80421-X
        • Beck M
        • Wust P
        • Barelkowski T
        • et al.
        Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
        Radiat Oncol Lond Engl. 2017; 12https://doi.org/10.1186/s13014-017-0862-4
        • Zilli T
        • Jorcano S
        • Peguret N
        • et al.
        Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis.
        Acta Oncol Stockh Swed. 2014; 53: 96-102https://doi.org/10.3109/0284186X.2013.837584
        • Ost P
        • Lumen N
        • Goessaert AS
        • et al.
        High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
        Eur Urol. 2011; 60: 842-849https://doi.org/10.1016/j.eururo.2011.04.021
        • Lock MI
        • Heinrichs A
        • Bhattacharya G
        • et al.
        The utility of penile bulb contouring to localise the prostate apex as compared to urethrography.
        J Med Imaging Radiat Sci. 2018; 49: 76-83https://doi.org/10.1016/j.jmir.2017.10.002
        • PROSTATE BED DELINEATION GUIDELINES FOR POSTOPERATIVE RADIOTHERAPY
        On behalf of the GFRU (francophone group of urological radiotherapy).
        Int J Radiat Oncol. 2020; 10 (Published online November)https://doi.org/10.1016/j.ijrobp.2020.11.010
        • Brenneman R
        • Goddu SM
        • Michalski JM.
        Penile bulb inter-fraction organ motion during prostate cancer radiotherapy.
        in: Radiologic Society of North America (RSNA) Annual Meeting. 2020